Clinical Trial Update: YM598 in Patients With Rising PSA After Initial Therapy for Localized Prostate Cancer [Phase 2]

View source ↗

Summary

This update reports that YM598, an experimental therapy from Astellas, in Phase 2 testing for rising PSA after initial therapy in localized prostate cancer has …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• YM598

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Prostate Cancer | Phase 2 | Status: TERMINATED